TEL AVIV, Israel, and PARIS, Dec. 3, 2020 /PRNewswire/ -- Ibex Medical Analytics, a pioneer in artificial intelligence (AI)-based cancer diagnostics, and Institut Curie, France's leading cancer center, today announced a research partnership aimed at improving diagnosis of breast cancer with AI.
Breast cancer is the most common malignant disease in women worldwide, with over 2 million new cases each year. As such, accurate and timely diagnosis of breast cancer is instrumental in guiding treatment decisions and improving patient survival rates. Analysis of breast tissue samples by a pathologist, typically using gross exam followed by examination under a microscope of tissue sections from biopsies or surgical specimens, remains the standard method of diagnosing and staging cancer. However, in recent years, an increase in cancer prevalence, coupled with a decline in the number of pathologists specialized in diagnosing cancer, has resulted in greater workloads and relatively long wait times for test results. Clearly, there is a growing need for automated solutions and decision support tools that can help pathologists diagnose cancer to the utmost accuracy more rapidly, while enabling comprehensive and affordable quality control.
This research partnership, the first of its kind, will include a rich dataset of breast biopsy slides, digitized using a digital pathology scanner and analyzed for cancer detection by Ibex's Galen™ Breast solution. Independently, multiple pathologists from Institut Curie will diagnose the slides, followed by blinded analysis of the AI-solution's performance. Galen Breast, the first AI solution used for detection of breast cancer in pathology, was developed utilizing state-of-the-art AI and machine learning techniques, and trained on hundreds of thousands of image samples. The solution is already deployed at the pathology institute of Maccabi Healthcare Services, Israel's second largest HMO, where it is used as a second read application.
"The importance of breast pathology is ever increasing, as new and more personalized treatments for breast cancer become available, many of which are based on precision medicine and require more tests and diagnosis by pathologists," said Dr. Anne Vincent-Salomon, Director of Pathology at Institut Curie and the principal investigator in the study. "We believe that artificial intelligence can help us meet these challenges, and we are delighted to partner with Ibex, the leader in AI for cancer diagnosis in pathology. This collaboration will enable our pathologists to experience AI firsthand and evaluate its utility for diagnosing breast cancer."
"We are excited to partner with Institut Curie, a global leader in research and treatment of breast cancer, for the first-ever blinded and independent evaluation of an AI-solution for breast cancer detection," said Daphna Laifenfeld, PhD, Chief Scientific Officer at Ibex Medical Analytics. "Our Galen Prostate solution has demonstrated outstanding clinical outcomes and empowers pathologists worldwide to improve diagnostic accuracy and implement 100% quality control. We are continuing to expand our platform to new tissue types, focusing this time on breast biopsies, and are thrilled to work with Dr. Vincent-Salomon and her world-leading team on this important breast cancer study."
"This collaboration illustrates Institut Curie's approach to partnership-based research, combining the expertise of clinicians with the know-how of an innovation-driven technology company," added Amaury Martin, PhD, Head of Technology Transfer and Industrial Partnerships Office at Institut Curie and Head of Carnot Curie Cancer. "It illustrates our commitment to play a major role in the development of artificial intelligence approaches applied to personalized medicine."
Ibex will exhibit in the 32nd Congress of the European Society of Pathology, taking place virtually between December 6 and December 8. Access Ibex's virtual booth here: https://cpohanser.6connex.eu/event/virtual/en-us#!/Ibex_ESP-IAP (free registration is required).
About Ibex Medical Analytics
Ibex uses AI to develop clinical-grade solutions that help pathologists detect and grade cancer in biopsies. The Galen Prostate and Galen Breast are the first-ever AI-powered cancer diagnostics solutions in routine clinical use in pathology and deployed worldwide, empowering pathologists to improve diagnostic accuracy, integrate comprehensive quality control and enable more efficient workflows. Ibex's solutions are built on deep learning algorithms trained by a team of pathologists, data scientists and software engineers. For more information, go to www.ibex-ai.com
About Institut Curie
Institut Curie, France's leading cancer center, combines an internationally-renowned research center with a cutting-edge hospital group that treats all types of cancer, including the rarest. Founded in 1909 by Marie Curie, Institut Curie employs 3,500 researchers, physicians, and health professionals across three sites (Paris, Saint-Cloud, and Orsay), working on its three missions: treatment, research, and teaching. A private foundation with public utility status, Institut Curie is authorized to receive donations and legacies, and thanks to the support of its donors, is able to make discoveries more quickly, improving treatments and quality of life for patients. For more information, visit www.curie.fr
Media Contacts
Laura Raanan
GK for Ibex
laura@gkpr.com
Elsa Champion
Institut Curie
elsa.champion@curie.fr
View original content to download multimedia:http://www.prnewswire.com/news-releases/ibex-medical-analytics-and-institut-curie-partner-to-improve-ai-powered-breast-cancer-detection-301185641.html
SOURCE Ibex Medical Analytics; Institut Curie
"breast" - Google News
December 03, 2020 at 11:51PM
https://ift.tt/33HaETQ
Ibex Medical Analytics and Institut Curie Partner to Improve AI-Powered Breast Cancer Detection - BioSpace
"breast" - Google News
https://ift.tt/2ImtPYC
https://ift.tt/2Wle22m
Bagikan Berita Ini
0 Response to "Ibex Medical Analytics and Institut Curie Partner to Improve AI-Powered Breast Cancer Detection - BioSpace"
Post a Comment